Regulatory role of miRNAs in nasopharyngeal cancer involving PTEN/PI3K/AKT, TGFβ/SMAD, RAS/MAPK, Wnt/β-catenin and pRB-E2F signaling pathways: A review.
Humans
Nasopharyngeal Neoplasms
/ genetics
MicroRNAs
/ genetics
Proto-Oncogene Proteins c-akt
/ metabolism
Phosphatidylinositol 3-Kinases
/ metabolism
beta Catenin
/ metabolism
Transforming Growth Factor beta
/ metabolism
Carcinoma
Nasopharyngeal Carcinoma
/ genetics
Signal Transduction
Cell Proliferation
Gene Expression Regulation, Neoplastic
Cell Line, Tumor
Cell Movement
/ genetics
PTEN Phosphohydrolase
/ genetics
cancer
disease
microRNA
nasopharyngeal Cancer
onco-mir
tumor suppressor-miR
Journal
Cell biochemistry and function
ISSN: 1099-0844
Titre abrégé: Cell Biochem Funct
Pays: England
ID NLM: 8305874
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
15
01
2024
received:
26
09
2023
accepted:
17
01
2024
medline:
19
2
2024
pubmed:
16
2
2024
entrez:
16
2
2024
Statut:
ppublish
Résumé
MicroRNAs (miRNA) are small and conserved noncoding RNA molecules that regulate gene expression at the posttranscriptional level. These groups of RNAs are crucial in various cellular processes, especially in mediating disease pathogenesis, particularly cancer. The dysregulation of miRNAs was reported in many cancer types, including nasopharyngeal cancer (NPC), which is a malignant tumor of the nasopharynx. In this review, miRNAs involvement in crucial signaling pathways associated with NPC such as PTEN/PI3K/AKT, TGFβ/SMAD, RAS/MAPK, Wnt/β-catenin and pRB-E2F was investigated. miRNAs could function as tumor suppressor-miR or onco-miR in NPC profoundly influenced cell cycle, apoptosis, proliferation, migration, and metastasis. This comprehensive review of current literature provided a thorough profile of miRNAs and their interplay with the aforementioned signaling pathways in NPC. Understanding these molecular interactions could remarkably impact the diagnosis, prognosis, and therapeutic strategies for NPC.
Substances chimiques
MicroRNAs
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
beta Catenin
0
Transforming Growth Factor beta
0
PTEN protein, human
EC 3.1.3.67
PTEN Phosphohydrolase
EC 3.1.3.67
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3945Subventions
Organisme : Fundamental Research Grant Scheme
ID : FRGS/1/2021/SKK03/USM/02/3
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Liao W, Tian M, Chen N. Characteristic and novel therapeutic strategies of nasopharyngeal carcinoma with synchronous metastasis. Cancer Manag Res. 2019;11:8431‐8442.
Tsao SW, Yip YL, Tsang CM, et al. Etiological factors of nasopharyngeal carcinoma. Oral Oncol. 2014;50(5):330‐338.
Mahdavifar N, Ghoncheh M, Mohammadian‐Hafshejani A, Khosravi B, Salehiniya H. Epidemiology and inequality in the incidence and mortality of nasopharynx cancer in Asia. Osong Public Health Res Perspect. 2016;7(6):360‐372.
MacFarlane LA, Murphy R. P. MicroRNA: biogenesis, function and role in cancer. Curr Genomics. 2010;11(7):537‐561.
Rajasegaran Y, Azlan A, Rosli AA, et al. Footprints of microRNAs in cancer biology. Biomedicines. 2021;9(10):1494.
Spence T, Bruce J, Yip KW, Liu FF. MicroRNAs in nasopharyngeal carcinoma. Chin Clin Oncol. 2016;5(2):17.
Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167‐179.
Almeida MI, Reis RM, Calin GA. Decoy activity through microRNAs: the therapeutic implications. Expert Opin Biol Ther. 2012;12(9):1153‐1159.
Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma. Br J Haematol. 2008;141(5):672‐675.
Wang F, Lu J, Peng X, et al. Integrated analysis of microRNA regulatory network in nasopharyngeal carcinoma with deep sequencing. J Exp Clin Cancer Res. 2016;35:1‐11.
Wang H, Peng R, Wang J, Qin Z, Xue L. Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clin Epigenetics. 2018;10(1):59.
Jeansonne D, DeLuca M, Marrero L, et al. Anti‐tumoral effects of miR‐3189‐3p in glioblastoma. J Biol Che. 2015;290(13):8067‐8080.
Pinatel EM, Orso F, Penna E, et al. miR‐223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions. PLoS ONE. 2014;9(1):e84859.
Ben‐Hamo R, Efroni S. MicroRNA regulation of molecular pathways as a generic mechanism and as a core disease phenotype. Oncotarget. 2015;6(3):1594.
Chai R, Fu H, Zheng Z, Liu T, Ji S, Li G. Resveratrol inhibits proliferation and migration through SIRT1 mediated post‑translational modification of PI3K/AKT signaling in hepatocellular carcinoma cells. Mol Med Rep. 2017;16(6):8037‐8044.
Wang CH, Li XF, Jin LF, Zhao Y, Zhu GJ, Shen WZ. Dieckol inhibits non‐small–cell lung cancer cell proliferation and migration byregulating the PI3K/AKT signaling pathway. J Biochem Mol Toxicol. 2019;33(8):e22346.
Haddadi N, Lin Y, Travis G, Simpson AM, Nassif NT, McGowan EM. PTEN/PTENP1: ‘Regulating the regulator of RTK‐dependent PI3K/Akt signalling’, new targets for cancer therapy. Mol Cancer. 2018;17(1):37.
Chalhoub N, Baker SJ. PTEN and the PI3‐kinase pathway in cancer. Annu Rev Pathol: Mech Dis. 2009;4:127‐150.
Blanco‐Aparicio C, Renner O, Leal JFM, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis. 2007;28(7):1379‐1386.
Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell. 2000;100(4):387‐390.
Kang Y, He W, Ren C, et al. Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma. Signal Transduct Target Ther. 2020;5(1):245.
Zhang J, Wen X, Ren XY, et al. YPEL3 suppresses epithelial–mesenchymal transition and metastasis of nasopharyngeal carcinoma cells through the Wnt/β‐catenin signalling pathway. J Exp Clin Cancer Res. 2016;35:109.
Zhang H, Cao H, Xu D, Zhu K. MicroRNA‐92a promotes metastasis of nasopharyngeal carcinoma by targeting the PTEN/AKT pathway. Onco Targets Ther. 2016;9:3579‐3588.
Sun Z, Zhou L, Wu J, Wang W. MiR‐141‐3p enhances the proliferation, invasion and migration of CNE‐2 human nasopharyngeal carcinoma cells by promoting vimentin expression. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi Chin J Cell Mol Immunol. 2023;39(1):63‐69.
Wardana T, Chasanah SN, Oktriani R, et al. Circulation microRNA expression profiles in patients with complete responses to chemoradiotherapy in nasopharyngeal carcinoma. Non‐coding RNA Res. 2022;7(4):233‐241.
Li M, Huang H, Cheng F, Hu X, Liu J. MiR‐141‐3p promotes proliferation and metastasis of nasopharyngeal carcinoma by targeting NME1. Adv Med Sci. 2020;65(2):252‐258.
Gao R, Feng Q, Tan G. MicroRNA‐613 exerts anti‐angiogenic effect on nasopharyngeal carcinoma cells through inactivating the AKT signaling pathway by down‐regulating FN1. Biosci Rep. 2019;39(7)BSR20182196.
Zhou X, Xu H, Huang G, Lin B. Nasopharyngeal carcinoma derived exosomes regulate the proliferation and migration of nasopharyngeal carcinoma cells by mediating the miR‐99a‐5p BAZ2A axis. Braz J Otorhinolaryngol. 2024;90(1):101343.
Mao Y, Wu S, Zhao R, Deng Q. MiR‐205 promotes proliferation, migration and invasion of nasopharyngeal carcinoma cells by activation of AKT signalling. J Int Med Res. 2016;44(2):231‐240.
Wang G, Zhu J, Wang Z, Xu Z, Shi Y, Luo L. Curcumin increases radiosensitivity of radioresistant nasopharyngeal cancer. Discov Med. 2023;35(176):418‐428.
Huang Q, Hou S, Zhu X, Liu S. MicroRNA‐192 promotes the development of nasopharyngeal carcinoma through targeting RB1 and activating PI3K/AKT pathway. World J Surg Oncol. 2020;18:29.
He Q, Ren X, Chen J, et al. MiR‐16 targets fibroblast growth factor 2 to inhibit NPC cell proliferation and invasion via PI3K/AKT and MAPK signaling pathways. Oncotarget. 2016;7(3):3047‐3058.
Liao Z, Zhao L, Zhong F, et al. Serum and urine metabolomics analyses reveal metabolic pathways and biomarkers in relation to nasopharyngeal carcinoma. Rapid Commun Mass Spectrom. 2023;37(6):e9469.
Zhang G, Zhou H, Xiao H, Liu Z, Tian H, Zhou T. MicroRNA‐92a functions as an oncogene in colorectal cancer by targeting PTEN. Dig Dis Sci. 2014;59:98‐107.
Zhang SQ, Liu J, Chen HB, et al. A novel three‐microRNA signature for predicting survival in patients with nasopharyngeal carcinoma. J Dental Sci. 2022;17(1):377‐388.
Zhao M, Luo R, Liu Y, et al. MiR‐3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1‐modulated positive feedback loop with mTOR–p‐PI3K/AKT‐c‐JUN. Nat Commun. 2016;7(1):11309.
Fan K, Zhu H, Qi L, Huang Y, Xia X, Wu K. MiR‐137 regulates proliferation, migration, invasion and EMT of nasopharyngeal carcinoma cells by targeting TWIST1. Sci Adv Mater. 2023;15(3):361‐368.
Zhang ZZ, Cao HC, Huang DL, et al. MicroRNA‐200c plays an oncogenic role in nasopharyngeal carcinoma by targeting PTEN. Tumor Biol. 2017;39(5):101042831770365.
Luo H, Zhong F, Jing X, Lin H, Li Y. MiRNA profiling of human nasopharyngeal carcinoma cell lines HONE1 and CNE2 after x‐ray therapy. Adv Clin Exp Med. 2022;31(6):671‐687.
Zhang S, Wang B, Zheng L, et al. Advances in research on microRNAs related to the invasion and metastasis of nasopharyngeal carcinoma. Curr Mol Pharmacol. 2022;15(3):463‐474.
Yang J, Wu SP, Wang WJ, et al. A novel miR‐200c/c‐myc negative regulatory feedback loop is essential to the EMT process, CSC biology and drug sensitivity in nasopharyngeal cancer. Exp Cell Res. 2020;391(2):111817.
Yang G, Zhou J, Guo Z, et al. MiR‐26b targets CEP135 gene to regulate nasopharyngeal carcinoma proliferation and migration by NF‐κB pathway. Mol Biotechnol. 2023;65:1857‐1868.
Li HL, Deng NH, He XS, Li YH. Small biomarkers with massive impacts: PI3K/AKT/mTOR signalling and microRNA crosstalk regulate nasopharyngeal carcinoma. Biomark Res. 2022;10(1):52.
Ge Y, Yan Z, Du M, et al. A summary of our serial study: mechanism of invasion and metastasis in nasopharyngeal carcinoma. Holistic Integr Oncol. 2023;2(1):21.
Deng L, Yin Q, Liu S, Luo D. MicroRNA‐613 enhances nasopharyngeal carcinoma cell radiosensitivity via the DNA methyltransferase 3B/tissue inhibitor of matrix metalloproteinase‐3/signal transducer and activator of transcription‐1/Forkhead box O‐1 axis. Dis Markers. 2022;2022:1‐14.
Shi Q, Dai J, Huang L. MicroRNA‐29a functions as a tumor suppressor in nasopharyngeal carcinoma 5‐8F cells through targeting VEGF. Iran J Basic Med Sci. 2019;22(5):541‐546.
Álvarez‐Garcia V, Tawil Y, Wise HM, Leslie NR. Mechanisms of PTEN loss in cancer: It's all about diversity. In Seminars in cancer biolobrgy. 59. Academic Press; 2019:66‐79.
Yu T. Cao R, Li S, et al. MiR‐130b plays an oncogenic role by repressing PTEN expression in esophageal squamous cell carcinoma cells. BMC Cancer. 2015;15:29.
Lei T, Yuen KS, Xu R, et al. Targeting of DICE1 tumor suppressor by Epstein–Barr virus‐encoded miR‐BART3* microRNA in nasopharyngeal carcinoma. Int J Cancer. 2013;133(1):79‐87.
Qu C, Liang Z, Huang J, et al. MiR‐205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. Cell Cycle. 2012;11(4):785‐796.
Ghafouri‐Fard S, Abak A, Shoorei H, et al. Regulatory role of microRNAs on PTEN signaling. Biomed Pharmacother. 2021;133:110986.
Yang Y, Ye WL, Zhang RN, et al. The role of TGF‐β signalling pathways in cancer and its potential as a therapeutic target. Evid Based Complementary Altern Med. 2021;2021:1‐16.
Zhao M, Mishra L, Deng CX. The role of TGF‐β/SMAD4 signaling in cancer. Int J Biol Sci. 2018;14(2):111‐123.
Ozaki I, Hamajima H, Matsuhashi S, Mizuta T. Regulation of TGF‐β1‐induced pro‐apoptotic signaling by growth factor receptors and extracellular matrix receptor integrins in the liver. Front Physiol. 2011;2:78.
Son HK, Kim D, Lim Y, Kim J, Park I. A novel TGF‐β receptor II mutation (I227T/N236D) promotes aggressive phenotype of oral squamous cell carcinoma via enhanced EGFR signaling. BMCCancer. 2020;20(1):1163.
Doerner AM, Zuraw BL. TGF‐β 1 induced epithelial to mesenchymal transition (EMT) in human bronchial epithelial cells is enhanced by IL‐1β but not abrogated by corticosteroids. Respir Res. 2009;10:100.
Soukupova J, Malfettone A, Bertran E, et al. Epithelial–mesenchymal transition (Emt) induced by tgf‐β in hepatocellular carcinoma cells reprograms lipid metabolism. IntJ Mol Sci. 2021;22(11):5543.
Suzuki H. MicroRNA control of TGF‐β signaling. Int J Mol Sci. 2018;19(7):1901.
Butz H, Rácz K, Hunyady L, Patócs A. Crosstalk between TGF‐β signaling and the microRNA machinery. Trends Pharmacol Sci. 2012;33(7):382‐393.
Xiao J, Xiang Q, Xiao YC, et al. The effect of transforming growth factor‐β1 on nasopharyngeal carcinoma cells: insensitive to cell growth but functional to TGF‐β/Smad pathway. J Exp Clin Cancer Res. 2010;29:1‐8.
Mestdagh P, Boström AK, Impens F, et al. The miR‐17‐92 microRNA cluster regulates multiple components of the TGF‐β pathway in neuroblastoma. Mol Cell. 2010;40(5):762‐773.
Wang H, Liu J, Zong Y, et al. MiR‐106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF‐β type II receptor. Brain Res. 2010;1357:166‐174.
Yu Y, Kanwar SS, Patel BB, et al. MicroRNA‐21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFβR2) in colon cancer cells. Carcinogenesis. 2012;33(1):68‐76.
Lyu X, Fang W, Cai L, et al. TGFβR2 is a major target of miR‐93 in nasopharyngeal carcinoma aggressiveness. Mol Cancer. 2014;13:51.
Wang J, Liu Y, Zhang Y, Li X, Fang M, Qian D. Targeting exosomes enveloped EBV‐miR‐BART1‐5p‐antagomiRs for NPC therapy through both anti‐vasculogenic mimicry and anti‐angiogenesis. Cancer Med. 2023;12:12608‐12621.
Skalsky RL. MicroRNA‐mediated control of Epstein–Barr virus infection and potential diagnostic and therapeutic implications. Curr Opin Virol. 2022;56:101272.
Tan G, Tang X, Tang F. The role of microRNAs in nasopharyngeal carcinoma. Tumor Biol. 2015;36:69‐79.
Li Y, Wang Y, Zhou H, Yong Y, Cao Y. MiR‐106b promoted growth and inhibited apoptosis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN. Int J Clin Exp Pathol. 2016;9(7):7078‐7086.
Zhang Z, Huang J, Wang G, et al. Serum miRNAs, a potential prognosis marker of loco‐regionally advanced nasopharyngeal carcinoma patients treated with CCRT. BMC Cancer. 2020;20:183.
Lao TD, Nguyen MT, Nguyen DH, Le TAH. Upregulation of miRNA‐155 in nasopharyngeal carcinoma patients. Iran J Publ Health. 2021;50(8):1642‐1647.
Chen M, Chen C, Luo H, et al. MicroRNA‐296‐5p inhibits cell metastasis and invasion in nasopharyngeal carcinoma by reversing transforming growth factor‐β‐induced epithelial–mesenchymal transition. Cell Mol Biol Lett. 2020;25(1):49.
Huang G, Du MY, Zhu H, et al. MiRNA‐34a reversed TGF‐β‐induced epithelial‐mesenchymal transition via suppression of SMAD4 in NPC cells. Biomed Pharmacother. 2018;106:217‐224.
Wu R, Zhong Q, Liu H, Liu S. MicroRNA‐577/EIF5A2 axis suppressed the proliferation of DDP‐resistant nasopharyngeal carcinoma cells by blocking TGF‐β signaling pathway. Chem Biol Drug Des. 2023;102(4):815‐827.
Guo G, Zhang Y, Hu L, Bian X. MicroRNA‑153 affects nasopharyngeal cancer cell viability by targeting TGF‑β2. Oncol Lett. 2019;17(1):646‐651.
Wang Y, Zhao Q, Lan N, Wang S. Identification of methylated genes and miRNA signatures in nasopharyngeal carcinoma by bioinformatics analysis. Mol Med Rep. 2018;17(4):4909‐4916.
Zeng X, Liao H, Wang F. MicroRNA‐384 inhibits nasopharyngeal carcinoma growth and metastasis via binding to Smad5 and suppressing the Wnt/β‐catenin axis. Cytotechnology. 2021;73:203‐215.
Cui F, Ji Y, Wang M, Gao F, Li Y, Li X. MiR‐143 inhibits proliferation and metastasis of nasopharyngeal carcinoma cells via targeting FMNL1 based on clinical and radiologic findings. J Cell Biochem. 2019;120(10):16427‐16434.
Lee T. The effect of cytokines on microRNA expression in TW01 nasopharyngeal carcinoma cells. Br J Med Med Res. 2013;3(3):543‐554.
Xu YF, Li YQ, Guo R, et al. Identification of miR‐143 as a tumour suppressor in nasopharyngeal carcinoma based on microRNA expression profiling. Int J Biochem Cell Biol. 2015;61:120‐128.
Wang X, Chen P. Aberrant miR‐362‐3p is associated with EBVinfection and prognosis in nasopharyngeal carcinoma and involved in tumor progression by targeting JMJD2A. Onco Targets Ther. 2022;15:121‐131.
Zhao X, Zhang XJ, Li L, Xia ST, Cheng L. MicroRNA‐326 inhibits cell proliferative capacity and invasiveness through inhibiting the expression of ETS1 in nasopharyngeal carcinoma. Eur Rev Med Pharmacol Sci. 2020;24(1):181‐188.
Pantsar T. The current understanding of KRAS protein structure and dynamics. Comput Struct Biotechnol J. 2020;18:189‐198.
Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ. K‐Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3‐kinase signaling. Cancer Res. 2007;67(5):2098‐2106.
Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11‐22.
Huang X, Zhu X, Yu Y, et al. Dissecting miRNA signature in colorectal cancer progression and metastasis. Cancer Letters. 2021;501:66‐82.
Karachaliou N, Mayo C, Costa C, et al. KRAS mutations in lung cancer. Clin Lung Cancer. 2013;14(3):205‐214.
Zhu G, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer. 2021;20(1):143.
Chen X, Shi J, Zhong J, et al. MiR‐1, regulated by LMP1, suppresses tumour growth and metastasis by targeting K‐ras in nasopharyngeal carcinoma. Int J Exp Pathol. 2015;96(6):427‐432.
Lamei H, Zhixing G, Wang F, Liwu F. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6(1), doi:10.1038/s41392-021-00780-4
Du M, Chen W, Zhang W, et al. TGF‐β regulates the ERK/MAPK pathway independent of the SMAD pathway by repressing miRNA‐124 to increase MALAT1 expression in nasopharyngeal carcinoma. Biomed Pharmacother. 2018;99:688‐696.
Chen JH, Yang R, Zhang W, Wang YP. Functions of microRNA‑143 in the apoptosis, invasion and migration of nasopharyngeal carcinoma. Exp Ther Med. 2016;12(6):3749‐3755.
Deng M, Tang H, Zhou Y, et al. MiR‐216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. J Cell Sci. 2011;124(17):2997‐3005.
Zhang Y, Zhao Y, Liu L, et al. MicroRNA‐19b promotes nasopharyngeal carcinoma more sensitive to cisplatin by suppressing KRAS. Technol Cancer Res Treat. 2018;17:1533033818793652.
Liu F, Tai Y, Ma J. LncRNA NEAT1/let‐7a‐5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf‐1 and modulating the Ras‐MAPK pathway. Cancer Biol Ther. 2018;19(6):534‐542.
Siak PY, Heng WS, Teoh SSH, Lwin YY, Cheah SC Precision medicine in nasopharyngeal carcinoma: comprehensive review of past and future prospect. J Transl Med 2023;21(1)‐786
Zhu Q, Zhang Q, Gu M, et al. MIR106A‐5p upregulation suppresses autophagy and accelerates malignant phenotype in nasopharyngeal carcinoma. Autophagy. 2021;17(7):1667‐1683.
Chen S, Sun YY, Zhang ZX, Li YH, Xu ZM, Fu WN. Transcriptional suppression of microRNA‐27a contributes to laryngeal cancer differentiation via GSK‐3β‐involved Wnt/β‐catenin pathway. Oncotarget. 2017;8(9):14708‐14718.
Chiurillo MA. Role of the Wnt/β‐catenin pathway in gastric cancer: an in‐depth literature review. World J Exp Med. 2015;5(2):84.
Liu LJ, Xie SX, Chen YT, Xue JL, Zhang CJ, Zhu F. Aberrant regulation of wnt signaling in hepatocellular carcinoma. World J Gastroenterol. 2016;22(33):7486.
Peng Y, Zhang X, Feng X, Fan X, Jin Z. The crosstalk between microRNAs and the Wnt/β‐catenin signaling pathway in cancer. Oncotarget. 2017;8(8):14089‐14106.
Clevers H, Nusse R. Wnt/β‐catenin signaling and disease. Cell. 2012;149(6):1192‐1205.
Cheng Y, Phoon YP, Lung ML. Abstract 1938: inhibition of both physiological and aberrant Wnt/β‐catenin signaling activities associated with stemness in nasopharyngeal carcinoma. Cancer Res. 2014;74(19 suppl):1938.
Wang Z, Wang Y, Ren H, Jin Y, Guo Y. ZNRF3 inhibits the invasion and tumorigenesis in nasopharyngeal carcinoma cells by inactivating the Wnt/β‐catenin pathway. Oncol Res. 2017;25(4):571‐577.
Wang S, Yang T, He Z. Investigations on the role of the MicroRNA‐338‐5p/Wnt family member 2B (WNT2B) axis in regulating the pathogenesis of nasopharyngeal carcinoma (NPC). Front Oncol. 2021;11:684462.
Cheng C, Li W, Peng X, et al. MiR‐1254 induced by NESG1 inactivates HDGF/DDX5‐stimulated nuclear translocation of β‐catenin and suppresses NPC metastasis. Mol Ther Methods Clin Dev. 2021;20:615‐624.
Hu H, Wang G, Li C. MiR‐124 suppresses proliferation and invasion of nasopharyngeal carcinoma cells through the Wnt/β‐catenin signaling pathway by targeting Capn4. Onco Targets Ther. 2017;10:2711‐2720.
Xia H, Ng SS, Jiang S, et al. MiR‐200a‐mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem Biophys Res Commun. 2010;391(1):535‐541.
Zhao Y, Gu X, Wang Y. MicroRNA‐103 promotes nasopharyngeal carcinoma through targeting TIMP‐3 and the Wnt/β‐catenin pathway. Laryngoscope. 2020;130(3):E75‐E82.
Sparmann A, Van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006;6(11):846‐856.
Lu J, He ML, Wang L, et al. MiR‐26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 2011;71(1):225‐233.
Yu L, Lu J, Zhang B, et al. MiR‐26a inhibits invasion and metastasis of nasopharyngeal cancer by targeting EZH2. Oncology letters. 2013;5(4):1223‐1228.
Tong ZT, Cai MY, Wang XG, et al. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co‐repressor complex with HDAC1/HDAC2 and Snail to inhibit E‐cadherin. Oncogene. 2012;31(5):583‐594.